Silo Pharma, Inc. announced today, 2025‑10‑23, a comprehensive update on progress in its PTSD drug development program and the launch of a new digital assets treasury strategy. The company highlighted that its lead intranasal candidate SPC‑15 is in the final preparation phase for an investigational new drug (IND) submission to the U.S. Food and Drug Administration, following positive results from a large‑animal safety/toxicology study. This regulatory milestone brings the company closer to initiating Phase 1 clinical trials and represents a significant step in the commercialization pathway for SPC‑15.
The update also covered the company’s cryptocurrency treasury program, which was launched in early August 2025. Silo has made four investments in leading digital assets, employing a staking‑yield model combined with a hedged overlay to mitigate volatility while preserving upside potential. The strategy is intended to diversify capital, generate yield, and strengthen the company’s financial foundation for future drug development activities. CEO Eric Weisblum emphasized that the program’s early achievements demonstrate confidence in blockchain technology’s growth and its role as a store of value.
Silo’s CEO noted that the company is preparing to submit the SPC‑15 IND in 2026, and that the digital assets strategy is positioned for success through its partnership with Fireblocks for institutional‑grade security and technology. The announcement underscores a dual‑track approach: advancing a potentially transformative therapy for PTSD while simultaneously exploring alternative capital markets to support R&D. For investors, the combined progress signals both a tangible regulatory advance and a proactive diversification of funding sources, potentially enhancing the company’s long‑term value proposition.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.